F-18 Fluorodeoxyglucose-Positron Emission Tomography Imaging for Primary Breast Cancer and Loco-Regional Staging

PET Clinics

Volumn 1, Issue 1, 2006, Pages 1-13

  Avril, Norbert ^a   Adler, Lee P ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Adler Institute for Advanced Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34249095611     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2005.09.008     Document Type: Review

References (53)

1. Sant M., Allemani C., Berrino F., et al. Breast carcinoma survival in Europe and the United States. Cancer 100 4 (2004) 715-722
2. Banerjee M., George J., Song E.Y., et al. Tree-based model for breast cancer prognostication. J Clin Oncol 22 13 (2004) 2567-2575
3. Fitzgibbons P.L., Page D.L., Weaver D., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124 7 (2000) 966-978
4. Sickles E.A. Breast masses: mammographic evaluation. Radiology 173 (1989) 297-303
5. Kopans D.B., and Feig S.A. False positive rate of screening mammography. N Engl J Med 339 8 (1998) 562-564
6. Kopans D.B. The positive predictive value of mammography. AJR Am J Roentgenol 158 (1992) 521-526
7. Liberman L., Menell J.H. Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am 2002;40(3):409-30, v
8. Meyer J.E., Eberlein T.J., Stomper P.C., et al. Biopsy of occult breast lesions. Analysis of 1261 abnormalities. JAMA 263 (1990) 2341-2343
9. Sickles E.A., Miglioretti D.L., Ballard-Barbash R., et al. Performance benchmarks for diagnostic mammography. Radiology 235 3 (2005) 775-790
10. Bird R.E., Wallace T.W., and Yankaskas B.C. Analysis of cancer missed at screening mammography. Radiology 184 (1992) 613-617
11. Fine R.E., Staren E.D. Updates in breast ultrasound. Surg Clin North Am 2004;84(4):1001-34, v-vi
12. Mendelson E.B. Problem-solving ultrasound. Radiol Clin North Am 2004;42(5):909-18, vii
13. Simmons R. Ultrasound in the changing approaches to breast cancer diagnosis and treatment. Breast J 10 Suppl 1 (2004) S13-S14
14. Lee C.H.. Problem solving MR imaging of the breast. Radiol Clin North Am 2004;42(5):919-34, vii
15. Hylton N. Magnetic resonance imaging of the breast: opportunities to improve breast cancer management. J Clin Oncol 23 8 (2005) 1678-1684
16. Chen X., Moore M.O., Lehman C.D., et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 11 10 (2004) 1115-1124
17. Rohren E.M., Turkington T.G., and Coleman R.E. Clinical applications of PET in oncology. Radiology 231 2 (2004) 305-332
18. Brown R.S., and Wahl R.L. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 72 10 (1993) 2979-2985
19. Adler L.P., Crowe J.P., al-Kaisi N.K., et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2- deoxy-2-fluoro-D-glucose PET. Radiology 187 3 (1993) 743-750
20. Adler L.P., Faulhaber P.F., Schnur K.C., et al. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203 2 (1997) 323-327
21. Boerner A.R., Weckesser M., Herzog H., et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 26 3 (1999) 226-230
22. Avril N., Bense S., Ziegler S.I., et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 38 8 (1997) 1186-1191
23. Stahl A., Weber W.A., Avril N., et al. Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 39 8 (2000) 241-245
24. Minn H., and Soini I. F-18 fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Am J Clin Pathol 91 5 (1989) 535-541
25. Kubota K., Matsuzawa T., Amemiya A., et al. Imaging of breast cancer with F-18 fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 13 6 (1989) 1097-1098
26. Wahl R.L., Cody R.L., Hutchins G.D., et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy- D-glucose. Radiology 179 3 (1991) 765-770
27. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18 20 (2000) 3495-3502
28. Avril N., Dose J., Jänicke F., et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 14 6 (1996) 1848-1857
29. Schirrmeister H., Kuhn T., Guhlmann A., et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28 3 (2001) 351-358
30. Goerres G.W., Michel S.C., Fehr M.K., et al. Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13 7 (2003) 1635-1644
31. Baslaim M.M., Bakheet S.M., Bakheet R., et al. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 27 10 (2003) 1099-1104
32. Crippa F., Seregni E., Agresti R., et al. Association between F-18 fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25 10 (1998) 1429-1434
33. Krecke K.N., and Gisvold J.J. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 161 5 (1993) 957-960
34. Gilles R., Guinebretière J.-M., Lucidarme O., et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 191 (1994) 625-631
35. Paramagul C.P., Helvie M.A., and Adler D.D. Invasive lobular carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology 195 1 (1995) 231-234
36. Tse N.Y., Hoh C.K., Hawkins R.A., et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216 1 (1992) 27-34
37. Vranjesevic D., Schiepers C., Silverman D.H., et al. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med 44 8 (2003) 1238-1242
38. Avril N., Menzel M., Dose J., et al. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42 1 (2001) 9-16
39. Sacre R.A. Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings. Eur J Surg Oncol 12 2 (1986) 169-173
40. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 349 9069 (1997) 1864-1867
41. Greco M., Crippa F., Agresti R., et al. Axillary lymph node staging in breast cancer by 2-Fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 93 8 (2001) 630-635
42. Torrenga H., Licht J., van der Hoeven J.J., et al. Re: axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 93 21 (2001) 1659-1661
43. Avril N., Dose J., Jänicke F., et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88 17 (1996) 1204-1209
44. Wahl R.L., Siegel B.A., Coleman R.E., et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 22 2 (2004) 277-285
45. Kelemen P.R., Lowe V., and Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 3 1 (2002) 73-77
46. Fehr M.K., Hornung R., Varga Z., et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 10 2 (2004) 89-93
47. Barranger E., Grahek D., Antoine M., et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 10 6 (2003) 622-627
48. Eubank W.B., Mankoff D.A., Takasugi J., et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19 15 (2001) 3516-3523
49. Murthy K., Aznar M., Thompson C.J., et al. Results of preliminary clinical trials of the positron emission mammography system PEM-I: a dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med 41 11 (2000) 1851-1858
50. Bergman A.M., Thompson C.J., Murthy K., et al. Technique to obtain positron emission mammography images in registration with x-ray mammograms. Med Phys 25 11 (1998) 2119-2129
51. Weinberg I., Majewski S., Weisenberger A., et al. Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med 23 7 (1996) 804-806
52. Weinberg I.N., Beylin D., Zavarzin V., et al. Positron emission mammography: high-resolution biochemical breast imaging. Technol Cancer Res Treat 4 1 (2005) 55-60
53. Tafra L., Cheng Z., Uddo O., et al. Pilot clinical trial of FDG positron emission mammography (PEM) in the surgical management of breast cancer. Am J Surg 190 (2005) 628-632